← All organizations
Highest phase reached
Phase 4
First clinical trial
Apr 1, 1995First marketed drug
May 17, 1996First NDA
May 17, 1996Last known activity
Jan 30, 2026
Acquired by Biogen-IDEC on Jan 1, 2003
Timeline
1970s
- Jan 1, 1978
Biogen— Founded
1990s
- May 17, 1996
interferon beta-1a— NDA Organization
- May 17, 1996
interferon beta-1a— NDA Secondary Org
2000s
- Jan 1, 2003
Biogen-IDEC— Acquired By
2020s
- Aug 4, 2023
zuranolone— Marketing Organization
- Jun 12, 2024
HI-Bio— Acquired
Drugs by trial phase (158 distinct, 415 trials)
Phase 4 (29 own, 0 via acquisition)
Phase 3 (34 own, 1 via acquisition)
Phase 2 (50 own, 0 via acquisition)
Phase 1 (42 own, 1 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- AIDS-Related Complex
- Alzheimer Disease
- Amyloidosis
- Amyotrophic Lateral Sclerosis
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Astrocytoma
- Atrophy
- Autoimmune Diseases
- Brain Contusion
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Cerebellar Diseases
- Cerebral Infarction
- Churg-Strauss Syndrome
- Cognitive Dysfunction
- Colitis
- Colitis, Ulcerative
- Colorectal Neoplasms
- Connective Tissue Diseases
- Contusions
- Crohn Disease
- Dementia
- Demyelinating Diseases
- Dermatomyositis
- Diabetes Mellitus
- Diabetic Neuropathies
- Disease Progression
- Epilepsies, Partial
- Epilepsy
- Erythema
- Fatigue
- Fibrosis
- Flushing
- Gastrointestinal Stromal Tumors
- Glioblastoma
- Glioma
- Gliosarcoma
- Glomerulonephritis, IGA
- Graft vs Host Disease
- Heart Failure
- Hemophilia A
- Hemophilia B
- HIV Infections
- Hypertension
- Hypertension, Pulmonary
- Hyponatremia
- Idiopathic Pulmonary Fibrosis
- Immune Reconstitution Inflammatory Syndrome
- Immune System Diseases
- Ischemia
- Kidney Diseases
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukoencephalopathies
- Leukoencephalopathy, Progressive Multifocal
- Lichen Planus
- Liver Diseases
- Lung Neoplasms
- Lupus Erythematosus, Cutaneous
- Lupus Erythematosus, Systemic
- Lupus Nephritis
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Melanoma
- Mesothelioma
- Monoclonal Gammopathy of Undetermined Significance
- Motor Neuron Disease
- Multiple Myeloma
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Multiple System Atrophy
- Muscular Atrophy
- Muscular Atrophy, Spinal
- Myelitis
- Myelitis, Transverse
- Myositis
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Nephritis
- Neuralgia
- Neuritis
- Optic Neuritis
- Ovarian Neoplasms
- Pain
- Paraproteinemias
- Parkinson Disease
Marketed drugs (10)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT04972487Lead sponsorN/A—
- NCT04972487Study directorN/A—
- NCT07221669Lead sponsorPhase 3Jan 30, 2026
- NCT07221669OfficialPhase 3Jan 30, 2026
- NCT07297199OfficialPhase 1Jan 9, 2026
- NCT07297199Lead sponsorPhase 1Jan 9, 2026
- NCT07294144CollaboratorPhase 2Dec 31, 2025
- NCT07223723Lead sponsorPhase 4Dec 2, 2025
- NCT07223723OfficialPhase 4Dec 2, 2025
- NCT07225517OfficialPhase 1Dec 1, 2025
- NCT07219043Lead sponsorPhase 2Dec 1, 2025
- NCT07219043OfficialPhase 2Dec 1, 2025
- NCT07225517Lead sponsorPhase 1Dec 1, 2025
- NCT07149415OfficialPhase 1Sep 2, 2025
- NCT07149415Lead sponsorPhase 1Sep 2, 2025
Details
- Founded
- Geneva, CH Jan 1, 1978
- First NDA
- May 17, 1996
- Last known activity
- Jan 30, 2026
Designations held
- Orphan drug